Xencor reported $69.27M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
J&J USD 45.8B 4.97B Sep/2025
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Xencor USD 69.27M 1.34M Sep/2025